Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer

Acta Oncologica

Volumn 51, Issue 7, 2012, Pages 867-872

  Komatsu, Yoshito ^a   Yuki, Satoshi ^a   Sogabe, Susumu ^a   Fukushima, Hiraku ^a   Nakatsumi, Hiroshi ^a   Kobayashi, Yoshimitsu ^a   Iwanaga, Ichiro ^a   Nakamura, Michio ^b   Hatanaka, Kazuteru ^c   Miyagishima, Takuto ^d   Kudo, Mineo ^e   Munakata, Masaki ^f   Meguro, Takashi ^g   Tateyama, Miki ^h   Sakata, Yuh ^f  

^a HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^b SAPPORO CITY GENERAL HOSPITAL   (Japan)

^c Hakodate Municipal Hospital   (Japan)

^d KUSHIRO ROSAI HOSPITAL   (Japan)

^e SAPPORO HOKUYU HOSPITAL   (Japan)

^f Misawa City Hospital   (Japan)

^g Hokkaido Gastroenterology Hospital   (Japan)

^h Tomakomai Nisshou Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; EPISTAXIS; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; HYPERPIGMENTATION; HYPERTENSION; INOPERABLE CANCER; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OVERALL SURVIVAL; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RECURRENT CANCER; STOMATITIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HUMANS; HYPERTENSION; JAPAN; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; OXONIC ACID; SEVERITY OF ILLNESS INDEX; TEGAFUR; TREATMENT OUTCOME;

EID: 84866390964     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2012.682629     Document Type: Article

References (26)

1. Minagawa M, Makuuchi M, Torzilli G, Takayama T, Kawasaki S, Kosuge T, et al. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: Long-term results. Ann Surg 2000; 231:487-99. (Pubitemid 30185854)
2. Japanese Society for Cancer of the Colon and Rectum: Multi-Institutional Registry of Large Bowel Cancer in Japan, Vol. 17: Cases treated in 1995. Tokyo: 1999.
3. Japanese Society for Cancer of the Colon and Rectum: Multi-Institutional Registry of Large Bowel Cancer in Japan, Vol. 18: Cases treated in 1996. Tokyo: 2000.
4. Japanese Society for Cancer of the Colon and Rectum: Multi-Institutional Registry of Large Bowel Cancer in Japan, Vol. 21: Cases treated in 1997. Tokyo: 2001.
5. Japanese Society for Cancer of the Colon and Rectum: Multi-Institutional Registry of Large Bowel Cancer in Japan, Vol. 24: Cases treated in 1998. Tokyo: 2003.
6. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fl uorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-14.
7. Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fl uorouracil/folinic acid plus oxaliplatin as fi rst-line therapy for metastatic colorectal cancer. J Clin Oncol 2008;26:2006-12.
8. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatinbased chemotherapy as fi rst-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 2008;26:2013-9.
9. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fl uoropyrimidines in fi rst-line treatment of metastatic colorectal cancer: Results from the BICC-C Study. J Clin Oncol 2007;25:4779-86. (Pubitemid 350086481)
10. Garcia-Alfonso P, Munoz-Martin AJ, Alvarez-Suarez S, Jerez-Gilarranz Y, Riesco-Martinez M, Khosravi P, et al. Bevacizumab in combination with biweekly capecitabine and irinotecan, as fi rst-line treatment for patients with metastatic colorectal cancer. Br J Cancer 2010;103:1524-8.
11. Komatsu Y, Yuki S, Sogabe S, Fukushima H, Iwanaga I, Kudo M, et al. Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302). Oncology 2011;80:70-5.
12. Muro K, Boku N, Shimada Y, Tsuji A, Sameshima S, Baba H, et al. Irinotecan plus S-1 (IRIS) versus fl uorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: A randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol 2010;11:853-60.
13. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
14. Komatsu Y, Yuki S, Fuse N, Kato T, Miyagishima T, Kudo M, et al. Phase 1/2 clinical study of irinotecan and oral S-1 (IRIS) in patients with advanced gastric cancer. Adv Ther 2010;27:483-92.
15. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176-81. (Pubitemid 36962641)
16. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, et al. Development of a novel form of an oral 5-fl uorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fl uorouracil by two biochemical modulators. Anticancer Drugs 1996;7:548-57. (Pubitemid 26276346)
17. Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K, et al. Phase II study of S-1, a novel oral fl uorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. Br J Cancer 2000;83:141-5. (Pubitemid 30411708)
18. Shirao K, Ohtsu A, Takada H, Mitachi Y, Hirakawa K, Horikoshi N, et al. Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma. Cancer 2004;100:2355-61. (Pubitemid 38657882)
19. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fl uoropyrimidine. N Engl J Med 2007;357:1810-20. (Pubitemid 350044801)
20. Okamoto I, Yoshioka H, Morita S, et al, Ando M, Takeda K, Seto T. Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer: Results of a west Japan oncology group study. J Clin Oncol 2010; 28:5240-6.
21. Naito S, Eto M, Shinohara N, Tomita Y, Fujisawa M, Namiki M, et al. Multicenter phase II trial of S-1 in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 2010;28:5022-9.
22. Goto A, Yamada Y, Yasui H, Kato K, Hamaguchi T, Muro K, et al. Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. Ann Oncol 2006;17:968-73. (Pubitemid 43778988)
23. Shiozawa M, Akaike M, Sugano N, Tsuchida K, Yamamoto N, Morinaga S, et al. A phase II study of combination therapy with irinotecan and S-1 (IRIS) in patients with advanced colorectal cancer. Cancer Chemother Pharmacol 2010;66: 987-92.
24. Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E, et al. Bevacizumab beyond fi rst progression is associated with prolonged overall survival in metastatic colorectal cancer: Results from a large observational cohort study (BRiTE). J Clin Oncol 2008;26:5326-34.
25. Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, et al. Safety and effi cacy of fi rst-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fl uoropyrimidines in metastatic colorectal cancer: The BEAT study. Ann Oncol 2009;20:1842-7.
26. De Stefano A, Carlomagno C, Pepe S, Bianco R, De Placido S. Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients. Cancer Chemother Pharmacol 2011;68:1207-13.